You are here: Home » Current Affairs » Coronavirus » News
Business Standard

India tally rises to 440K; Patanjali launches ayurvedic drug for Covid-19

According to government data, the situation in India is not as alarming as some of the other countries, given a limited spread on a per-capita basis

Topics
Coronavirus | Coronavirus Vaccine | Patanjali Ayurved

Sukanya Roy  |  New Delhi 

India reported nearly 15,000 cases in the last 24 hours, taking the total to 440,215, an increase of 3.5% according to the Health Ministry.The country's death toll has crossed the 14,000 mark with 312 fatalities in a day. India is the fourth-most-affected country by total cases, and eighth by death toll.

According to government data, however, the situation in India is not as alarming as some of the other countries, given a limited spread on a per-capita basis. India has 30.04 cases per 100,000 population, which is just a little more than a third of the global average of 114.67, the health ministry has said, referring to the Situation Report 153, dated June 21.

In a piece of good news, India's rate fell to its pre-lockdown level of 8.5 per cent in the week ended June 21. The rate had spiked from 8.75 per cent in March to 23.5 per cent in April and peaked at 27 per cent in May.

Baba Ramdev-led Ayurved, meanwhile, is launching a medicine, 'Coronil', for treating Covid-19 in Haridwar today. Acharya Balkrishna, Chief Executive Officer (CEO) of Patanjali, had earlier this month claimed that an Ayurvedic medicine developed by the company has been able to cure Covid-19 patients within 5-14 days.

US President has issued a proclamation to suspend issuing of H-1B visas, which is popular among Indian IT professionals, along with other foreign work visas for the rest of the year. Trump said the step was essential to help millions of Americans have lost their jobs due to the current economic crisis.

Listen to the Podcast for more

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, June 23 2020. 12:32 IST
RECOMMENDED FOR YOU